Roivant launches Respivant Sciences

Roivant Sciences announced the launch of Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases. Respivant will be led by CEO Bill Gerhart, Executive Vice President for Clinical and Regulatory Ahmet Tutuncu, MD, PhD, and Executive Vice President for Development and Manufacturing Pravin Soni, PhD. Respivant’s pipeline is anchored by RVT-1601, an inhaled therapeutic being developed for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. RVT-1601 is a mast cell stabilizer with pleotropic immune modulating properties delivered directly to the lungs via a handheld aerosol device that produces a soft mist for patients to conveniently inhale. In a Phase 2a clinical trial, RVT-1601 demonstrated a statistically significant reduction in cough frequency among IPF patients after 14 days of treatment. Respivant plans to initiate a Phase 2b study for RVT-1601 in the first quarter of 2019.
https://thefly.com/landingPageNews.php?id=2791347